HSDT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HSDT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Helius Medical Technologies's other income expense for the Helius Medical Technologies's pretax income for the three months ended in Sep. 2024 was $0.39 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was $4.16 Mil.
The historical data trend for Helius Medical Technologies's Other Income (Expense) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helius Medical Technologies Annual Data | |||||||||||||||||||||
Trend | Mar14 | Mar15 | Mar16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Income (Expense) | Get a 7-Day Free Trial | 14.22 | 0.26 | 0.01 | 1.52 | 3.16 |
Helius Medical Technologies Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Income (Expense) | Get a 7-Day Free Trial | -0.74 | 1.20 | 0.91 | 1.66 | 0.39 |
Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.
Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helius Medical Technologies (NAS:HSDT) Other Income (Expense) Explanation
Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.
Dane Andreeff | director, 10 percent owner, officer: President and CEO | C/O ANDREEFF EQUITY ADVISORS L.L.C., 140 E. ST. LUCIA LANE, SANTA ROSA BEACH FL 32459 |
Jeffrey S Mathiesen | director, officer: CFO and Treasurer | 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167 |
Favit-van Pelt Antonella R. | officer: Chief Medical Officer | C/O HELIUS MEDICAL TECHNOLOGIES, INC., 642 NEWTOWN YARDLEY ROAD, NEWTOWN PA 18940 |
Paul Buckman | director | 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402 |
Sherrie L Perkins | director | 5033 TANGLE LANE, HOUSTON TX 77056 |
Jennifer Laux | officer: Chief Commercial Officer | 642 NEWTOWN YARDLEY ROAD, SUITE 100, NEWTOWN PA 18940 |
Thomas E Griffin | director | C/O ENTELLUS MEDICAL, INC., 3600 HOLLY LANE NORTH, SUITE 40, PLYMOUTH MN 55447 |
Blane Walter | director | 500 OLDE WORTHINGTON ROAD, WESTERVILLE OH 43082 |
Edward M Straw | director | C/O ESTEE LAUDER COMPANIES, 767 FIFTH AVENUE, NEW YORK NY 10153 |
Joyce N Laviscount | officer: See Remarks | 100 ENDO BOULEVARD, CHADDS FORD PA 19317 |
Huaizheng Peng | director | HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940 |
Philippe Deschamps | director, 10 percent owner, officer: President & CEO | 105 BRADFORD RD, SUITE 420, WEXFORD PA 15090 |
Mitch E Tyler | director | HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940 |
Jonathan Sackier | 10 percent owner, officer: Chief Medical Officer | HELIUS MEDICAL TECHNOLOGIES, INC., SUITE 400, 41 UNIVERSITY DRIVE, NEWTOWN PA 18940 |
A&b (hk) Co Ltd | 10 percent owner | 8/F BLDG A TONGFANG INFORMATION HARBOR, NO 11 LANGSHAN ROAD NANSHAN DISTRICT, SHENZHEN F4 518057 |
From GuruFocus
By Marketwired • 11-18-2024
By GuruFocus Research • 08-13-2024
By GuruFocus Research • 05-14-2024
By Marketwired • 10-18-2024
By GlobeNewswire • 10-14-2024
By ACCESSWIRE • 05-31-2024
By GuruFocus Research • 08-13-2024
By GuruFocus Research • 05-14-2024
By GlobeNewswire • 05-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.